Cerus Corporation
Compositions and methods for improved car-T cell therapies

Last updated:

Abstract:

The present invention relates to the preparation and use in recipients of CAR-T cell-derived effector cells which are modified to limit their proliferation within the recipient. This is accomplished through the introduction of adducts into the nucleic acids of CAR-T cell-derived effector cells following expansion in vitro to provide expanded and activated CAR-T cell-derived effector cells that retain immunologic function, including the expression of one ore more cytokines.

Status:
Grant
Type:

Utility

Filling date:

2 Nov 2015

Issue date:

23 Jun 2020